Lupin Acquires Australia’s Southern Cross
Builds Up Position In Australia By Adding Portfolio Worth Over $22m
Executive Summary
Lupin has broadened its reach in Australia after agreeing a deal to buy local generics developer and distributor Southern Cross.
You may also be interested in...
GBMA Welcomes Australian Investment
Australia’s GBMA off-patent industry association has welcomed the announcement of significant healthcare investment in the country’s federal budget.
Australia Extends Biosimilar Education Efforts
Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.
Australia Plans Accelerated Approvals
Australia’s Therapeutic Goods Administration has proposed a range of mechanisms to reduce regulatory burden on companies with the explicit aim of addressing medicines shortages.